Table 2 Comparison of miR-197 expression levels according to clinicopathologic characteristics in diffuse large B cell lymphoma patients
From: Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma
| Variables | Full cohort (n = 51) | R-CHOP cohort (n = 43) | ||
|---|---|---|---|---|
| Mean ± SD | p value | Mean ± SD | p value | |
| Age, years | 0.415 | 0.357 | ||
| < 60 | 18.2 ± 32.6 | 7.8 ± 12.0 | ||
| ≥ 60 | 12.0 ± 13.7 | 11.6 ± 13.4 | ||
| Sex | 0.603 | 0.353 | ||
| Male | 16.0 ± 27.7 | 8.5 ± 10.4 | ||
| Female | 12.5 ± 15.4 | 12.2 ± 15.4 | ||
| Primary site | 0.504 | 0.595 | ||
| Nodal | 11.5 ± 15.3 | 8.6 ± 14.3 | ||
| Extranodal | 16.2 ± 26.8 | 10.8 ± 12.3 | ||
| Ann Arbor stage | 0.379 | 0.731 | ||
| I, II | 17.3 ± 29.2 | 10.7 ± 12.8 | ||
| III, IV | 11.5 ± 14.1 | 9.4 ± 13.2 | ||
| IPI groupa | 0.664 | 0.985 | ||
| Low (0–2) | 11.2 ± 13.0 | 10.1 ± 12.3 | ||
| High (3–5) | 13.0 ± 15.6 | 10.1 ± 14.1 | ||
| B symptomsa | 0.737 | |||
| Absent | 15.7 ± 27.4 | 10.4 ± 12.2 | ||
| Present | 13.4 ± 15.6 | 9.5 ± 14.4 | ||
| ECOG PSa | 0.886 | 0.310 | ||
| 0, 1 | 12.0 ± 13.8 | 10.9 ± 13.5 | ||
| ≥ 2 | 12.8 ± 16.0 | 5.1 ± 5.9 | ||
| LDHa | 0.466 | 0.785 | ||
| Normal | 10.2 ± 13.2 | 9.5 ± 12.6 | ||
| Elevated | 13.2 ± 14.6 | 10.6 ± 13.3 | ||
| BM involvementa | 0.561 | 0.452 | ||
| Absent | 11.0 ± 12.5 | 9.1 ± 11.2 | ||
| Present | 19.2 ± 24.8 | 24.1 ± 27.9 | ||
| Number of extranodal sitesa | 0.182 | 0.582 | ||
| 0, 1 | 12.9 ± 15.0 | 10.7 ± 14.0 | ||
| ≥ 2 | 8.1 ± 8.0 | 8.1 ± 8.0 | ||
| EBER | 0.820 | 0.804 | ||
| Negative | 14.1 ± 24.4 | 9.9 ± 11.2 | ||
| Positive | 16.0 ± 19.8 | 11.2 ± 20.4 | ||
| Hans classification | 0.253 | 0.833 | ||
| GCB | 20.7 ± 38.0 | 9.4 ± 11.5 | ||
| Non-GCB | 12.2 ± 14.6 | 10.4 ± 13.5 | ||
